NEW YORK — Women with ovarian cancer and diabetes who took the generic diabetes drug metformin showed better survival rates than those who did not take the drug, according to a new study led by the Mayo Clinic.
The study, published in the journal Cancer, enrolled 61 patients who took metformin and 178 who didn't. Of those who took the drug, 67% were surviving after five years, compared with 47% of those who didn't take it. Further analysis indicated that patients taking metformin were almost four times likelier to survive than those not taking it.
